MLH1 and non-small cell lung carcinoma: In addition, NTRK fusions were detected in other more common cancer types, such as papillary thyroid carcinoma, gastrointestinal stromal tumor (GIST), gliomas, non-small cell lung cancer (NSCLC), colorectal carcinoma (most frequently found in MSI-high carcinoma associated with MLH1 promoter hypermethylation), as well as malignant melanomas, uterine sarcomas, and pancreatic adenocarcinomas, however in less than 1% of all solid tumors overall [3, 6, 22–35].